Good, objective piece. Salient point... Viruses mutates and there's the strong likelihood that at some point, these MABs, even in combo, are likely to be useless.

Quote:

---

Monoclonal antibodies have crashed and burned too. Although many such drugs have ended up as transformative treatments, at least 21 of them failed in Phase III trials between 2014 and 2017. One of those was developed by Regeneron for a respiratory virus in infants: After being fast-tracked by the FDA on the basis of initial, “promising” results, the drug was abandoned in 2017. The trialists surmised that the problems they encountered—including the emergence of a mutant strain of the virus—might be overcome by delivering two different antibodies at once. That’s the design of the drug now being tested for Covid-19, and the same idea yielded exciting results for Ebola last year. So fingers crossed!

---